List View

By /

Clear

Displaying 2,376 - 2,400 of 2,573

ALK, ROS-1 and RET

ALK, ROS-1 and RET

MET, RAF and NTRK

MET, RAF and NTRK

KRAS and EGFR Exon 20 Insertion

KRAS and EGFR Exon 20 Insertion

Antibody Drug Conjugates in NSCLC

Antibody Drug Conjugates in NSCLC

Immunotherapy in Metastatic NSCLC: How to Choose Initial Therapy and What’s New?

Immunotherapy in Metastatic NSCLC: How to Choose Initial Therapy and What’s New?

Efforts to Overcome Resistance to First Line Immunotherapy

Efforts to Overcome Resistance to First Line Immunotherapy

Master Lecture on HER-2 in Breast Cancer

Master Lecture on HER-2 in Breast Cancer

Master Lecture on Endocrine Therapy in Early/Advanced Breast Cancer

Master Lecture on Endocrine Therapy in Early/Advanced Breast Cancer

Master Lecture on Triple Negative Breast Cancer

Master Lecture on Triple Negative Breast Cancer

Master Lecture on Ovarian, Fallopian Tube and Uterine Carcinomas

Master Lecture on Ovarian, Fallopian Tube and Uterine Carcinomas

Master Lecture on Prostate Cancer: Targeted Therapy PSMA and More

Master Lecture on Prostate Cancer: Targeted Therapy PSMA and More

Master Lecture on Kidney and Bladder Cancer

Master Lecture on Kidney and Bladder Cancer

Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 1)

Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 1)

Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 2)

Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 2)

Masters Debate on: ctDNA in Stage II, Stage III, and Post Resection of Oligometastatic Disease (Part 1)

Masters Debate on: ctDNA in Stage II, Stage III, and Post Resection of Oligometastatic Disease (Part 1)

Masters Debate on: ctDNA in Stage II, Stage III, and Post Resection of Oligometastatic Disease (Part 2)

Masters Debate on: ctDNA in Stage II, Stage III, and Post Resection of Oligometastatic Disease (Part 2)

Masters Lecture on Best Neoadjuvant Approaches for Rectal Cancer

Masters Lecture on Best Neoadjuvant Approaches for Rectal Cancer

Master Lecture on Advances in Pancreatic and Biliary Tract Carcinomas

Master Lecture on Advances in Pancreatic and Biliary Tract Carcinomas

Novel Advances and Updates in the Treatment of Colorectal Cancer

Novel Advances and Updates in the Treatment of Colorectal Cancer

Master Lecture on Small Cell: The Updates

Master Lecture on Small Cell: The Updates

Master Lecture on Targeting NSCLCDriver Pathways

Master Lecture on Targeting NSCLCDriver Pathways

Master Lecture on Immunotherapy in NSCLC: Metastatic Setting and What is After First Line IO Failure

Master Lecture on Immunotherapy in NSCLC: Metastatic Setting and What is After First Line IO Failure

Master Lecture on Antibody Drug Conjugates & Bispecific Antibodies in NSCLC

Master Lecture on Antibody Drug Conjugates & Bispecific Antibodies in NSCLC

Immunotherapy Updates in Head andNeck Cancer

Immunotherapy Updates in Head andNeck Cancer

Targeted Therapy Updates in Multiple Myeloma

Targeted Therapy Updates in Multiple Myeloma